<?xml version="1.0" encoding="UTF-8"?>
<p>Preliminary data based on molecular docking analyses predict several natural plant products as RBD interface binding compounds (
 <xref rid="B21" ref-type="bibr">Chikhale et al., 2020a</xref>; 
 <xref rid="B22" ref-type="bibr">Chikhale et al., 2020b</xref>; 
 <xref rid="B106" ref-type="bibr">Sinha et al., 2020a</xref>; 
 <xref rid="B107" ref-type="bibr">Sinha et al., 2020b</xref>; 
 <xref rid="T3" ref-type="table">Table 3</xref>). Most data come from “conceivable therapeutics” through 
 <italic>in silico</italic> molecular analysis of available structural macromolecules. An advantage to the preliminary 
 <italic>in silico</italic> screening of substances is that pharmacokinetic properties, such as safety could be easily established, shifting priority to the 
 <italic>in vitro</italic> confirmation of efficacy. Thus, preliminary evidences necessitate further 
 <italic>in vitro</italic> and 
 <italic>in vivo</italic> investigations. Notably, Wang and co-workers have recently identified AXL, a transmembrane tyrosine-protein kinase, as a supportive pulmonary entry receptor for the SARS-CoV-2 which may also interact with the spike glycoprotein, but at its NTD region (
 <xref rid="B125" ref-type="bibr">Wang et al., 2021</xref>). This represents another potential target for plant based therapeutic investigations.
</p>
